Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada
December 01 2021 - 8:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that Pasithea Clinics, its
wholly owned subsidiary, has expanded the availability of its
intravenous (“IV”) ketamine therapy to patients in Florida and
Nevada. Ketamine was introduced to the medical community as an
anesthetic more than 50 years ago and in sub-anesthetic doses has
shown remarkable efficacy in the treatment of certain psychiatric
conditions, such as treatment-resistant depression (“TRD”) and
post-traumatic stress disorder (“PTSD”).
“In November, we opened our first U.S. mobile
clinics in New York and California, and we’re pleased to announce
that our in-home IV ketamine infusion therapy is now available in
Nevada and Florida,” said Dr. Tiago Reis Marques, CEO of Pasithea
Therapeutics. “The pandemic has exacerbated the mental health
crisis and the number of patients suffering from depression
increased by approximately 25% in the past year. Today, up to three
million Americans are known to have a diagnosis of
treatment-resistant depression. These patients often struggle to
complete day-to-day activities, and the effort required to visit a
physical clinic can feel overwhelming. By expanding access to
in-home treatment, we aim to close the treatment gap. Initially,
the treatment will be offered in Miami and Las Vegas and will
expand to other cities in these states in the coming weeks.
Pasithea mobile clinics are already available in New York City, Los
Angeles, San Diego, and San Francisco.”
“The efficacy of ketamine in improving symptoms
of some mental health disorders is well documented, and our mobile
clinics enable patients to receive therapy in the privacy and
comfort of their own homes while still under the care of an
experienced medical team. This type of program can be crucial for
people who struggle with treatment-resistant depression and is an
important step in expanding access to IV ketamine treatment. We
look forward to continuing our U.S. expansion in the coming
months,” concluded Dr. Adam Nadelson, Managing Director of Pasithea
Clinics in the United States.
Studies have shown that up to 70% of those who
receive IV ketamine treatment will eventually show a clinical
response. While the number of treatments suggested is done on a
case-by-case basis, a typical treatment plan consists of up to six
infusions over a period of two to three weeks.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company ContactDr.
Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Apr 2023 to Apr 2024